Moderna stock rebound modestly after the Q4 results, but the overall sentiment of the stock remains under pressure. Moderna shares have lost more than% since the beginning of the year. The strong last quarter results were boosted by the sale of around 297 million doses of its COVID-19 vaccine.
What’s next for the Moderna (NASDAQ: MRNA) stock? - https://gulfbrokers.com/en/moderna-stock-rebound-modestly-after-the-q4-results-whats-next-for-the-stock